Randomized, Double-blind, Placebo-controlled, Six-month Parallel-group Study to Assess Efficacy and Safety of Dutasteride 0.5mg Once Daily in Chinese Patients With Benign Prostatic Hyperplasia (BPH), Followed by a 12-month Open-label Treatment Phase.

Trial Profile

Randomized, Double-blind, Placebo-controlled, Six-month Parallel-group Study to Assess Efficacy and Safety of Dutasteride 0.5mg Once Daily in Chinese Patients With Benign Prostatic Hyperplasia (BPH), Followed by a 12-month Open-label Treatment Phase.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Dutasteride (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Jan 2012 Primary endpoint 'Prostate-volume' has been met.
    • 01 Jan 2012 Results pertaining to both the core- and the extension study published in Clinical Drug Investigation.
    • 19 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top